공지 : 도쿄증권거래소 JASDAQ 스탠다드 시장 신규 상장 관련 안내

Global Information
회사소개 | 문의 | 비교리스트

세계의 간암 치료 시장(2021-2028년)

Global Liver Cancer Therapeutics Market - 2021-2028

리서치사 DataM Intelligence
발행일 On Demand Report 상품 코드 1008256
페이지 정보 영문 180 Pages
가격
US $ 4,350 ₩ 5,209,000 PDF & Excel (Single User License)
US $ 4,850 ₩ 5,807,000 PDF & Excel (Multiple User License)
US $ 7,850 ₩ 9,400,000 PDF & Excel (Enterprise License)


세계의 간암 치료 시장(2021-2028년) Global Liver Cancer Therapeutics Market - 2021-2028
발행일 : On Demand Report 페이지 정보 : 영문 180 Pages

본 상품은 영문 자료로 한글과 영문목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문목차를 참고해주시기 바랍니다.

간암 치료 시장의 성장은 간암 부담 증가, 연구개발 투자 개선, 새로운 치료법 창출, 암에 대한 인식을 높이기 위한 정부 이니셔티브에 의해 가속되고 있습니다. 현재의 라이프스타일 변화에 의해 많은 사람들이 특정 위험요인에 노출되어 있는 점이 예측기간 동안 간암 치료제 시장 확대에 기여할 것입니다.

세계의 간암 치료(Liver Cancer Therapeutics) 시장에 대해 조사했으며, 시장 기회와 영향, 시장 성장 촉진요인 및 억제요인, 종류·요법·기기·최종사용자·지역별 시장 분석, 경쟁 구도, 주요 기업 프로파일 등의 정보를 제공합니다.

목차

제1장 세계의 간암 치료 시장 조사 방법과 범위

  • 조사 방법
  • 조사 목적과 조사 범위

제2장 세계의 간암 치료 시장 : 시장의 정의와 개요

제3장 세계의 간암 치료 시장 : 개요

  • 유형별 시장 개요
  • 요법별 시장 개요
  • 기기별 시장 개요
  • 최종사용자별 시장 개요
  • 지역별 시장 개요

제4장 세계의 간암 치료 시장 : 시장 역학

  • 시장에 영향을 미치는 요인
    • 성장 촉진요인
    • 성장 억제요인
    • 시장 기회
    • 영향 분석

제5장 세계의 간암 치료 시장 : 업계 분석

  • Porter의 산업 분석
  • 공급망 분석
  • 가격 분석
  • 규제 분석
  • 상환 분석
  • 충족되지 않은 욕구

제6장 세계의 간암 치료 시장 : COVID-19 분석

  • 시장에서의 COVID-19 분석
    • COVID-19 이전의 시장 시나리오
    • 현재의 시장 시나리오
    • COVID-19 이후 또는 향후의 시나리오
  • COVID-19 가격 역학
  • 수급 스펙트럼
  • 팬데믹 기간의 시장에 관련된 정부 이니셔티브
  • 제조업체의 전략적 이니셔티브
  • 결론

제7장 세계의 간암 치료 시장 : 유형별

  • 서론
  • 시장 규모 분석 및 전년대비 성장 분석
  • 시장 매력도 지수
    • 간세포암
    • 담관암
    • 간아종
    • 기타

제8장 세계의 간암 치료 시장 : 요법별

  • 서론
  • 시장 규모 분석 및 전년대비 성장 분석
  • 시장 매력도 지수
    • 표적치료
    • 방사선치료
    • 면역치료
    • 화학요법

제9장 세계의 간암 치료 시장 : 기기별

  • 서론
  • 시장 규모 분석 및 전년대비 성장 분석
  • 시장 매력도 지수
    • 컴퓨터 X선 촬영
    • MRI
    • 초음파 검사
    • 기타

제10장 세계의 간암 치료 시장 : 최종사용자별

  • 서론
  • 시장 규모 분석 및 전년대비 성장 분석
  • 시장 매력도 지수
    • 병원
    • 클리닉
    • 외래수술센터(ASC)

제11장 세계의 간암 치료 시장 : 지역별

  • 서론
  • 시장 규모 분석 및 전년대비 성장 분석
  • 시장 매력도 지수
  • 북미
    • 서론
    • 주요 지역 고유의 역학
    • 유형별 : 시장 규모 분석 및 전년대비 성장 분석
    • 요법별 : 시장 규모 분석 및 전년대비 성장 분석
    • 기기별 : 시장 규모 분석 및 전년대비 성장 분석
    • 최종사용자별 : 시장 규모 분석 및 전년대비 성장 분석
    • 국가별 : 시장 규모 분석 및 전년대비 성장 분석
  • 유럽
    • 서론
    • 주요 지역 고유의 역학
    • 유형별 : 시장 규모 분석 및 전년대비 성장 분석
    • 요법별 : 시장 규모 분석 및 전년대비 성장 분석
    • 기기별 : 시장 규모 분석 및 전년대비 성장 분석
    • 최종사용자별 : 시장 규모 분석 및 전년대비 성장 분석
    • 국가별 : 시장 규모 분석 및 전년대비 성장 분석
  • 남미
    • 서론
    • 주요 지역 고유의 역학
    • 유형별 : 시장 규모 분석 및 전년대비 성장 분석
    • 요법별 : 시장 규모 분석 및 전년대비 성장 분석
    • 기기별 : 시장 규모 분석 및 전년대비 성장 분석
    • 최종사용자별 : 시장 규모 분석 및 전년대비 성장 분석
    • 국가별 : 시장 규모 분석 및 전년대비 성장 분석
  • 아시아태평양
    • 서론
    • 주요 지역 고유의 역학
    • 유형별 : 시장 규모 분석 및 전년대비 성장 분석
    • 요법별 : 시장 규모 분석 및 전년대비 성장 분석
    • 기기별 : 시장 규모 분석 및 전년대비 성장 분석
    • 최종사용자별 : 시장 규모 분석 및 전년대비 성장 분석
    • 국가별 : 시장 규모 분석 및 전년대비 성장 분석
  • 중동 및 아프리카
    • 서론
    • 주요 지역 고유의 역학
    • 유형별 : 시장 규모 분석 및 전년대비 성장 분석
    • 요법별 : 시장 규모 분석 및 전년대비 성장 분석
    • 기기별 : 시장 규모 분석 및 전년대비 성장 분석
    • 최종사용자별 : 시장 규모 분석 및 전년대비 성장 분석

제12장 세계의 간암 치료 시장 : 경쟁 구도

  • 경쟁 시나리오
  • 시장 포지셔닝/점유율 분석
  • 인수합병(M&A) 분석

제13장 세계의 간암 치료 시장 : 기업 개요

  • Amgen Inc.
    • 기업 개요
    • 제품 포트폴리오·개요
    • 요점
    • 재무 개요
  • AstraZeneca PLC
  • Bayer AG
  • Celgene Corporation
  • Eli Lilly
  • Bristol-Myers Squibb Company
  • Gilead Sciences, Inc.
  • Takeda Pharmaceutical Company Limited
  • Daiichi Sankyo Company, Limited
  • UCB SA

제14장 세계의 간암 치료 시장 : 프리미엄 인사이트

제15장 세계의 간암 치료 시장 : DataM

  • 부록
  • 당사 및 서비스에 대해
  • 문의
LSH 21.06.22

Market Overview

The global liver cancer therapeutics market size was valued US$ XX billion in 2020 and is estimated to reach US$ XX billion by 2028, growing at a CAGR of XX % during the forecast period (2021-2028).

Liver cancer is a chronic, life-threatening, and progressive disorder that begins in cells of the liver. The liver is the essential organ in the human body, located in the upper right of the abdomen beneath the right of the lungs. The liver essentially produces enzymes and bile to digest food. It also produces blood-clotting proteins and purifies the blood by removing harmful materials in it.

Market Dynamics

The liver cancer therapeutics market growth is driven by the increasing burden of liver cancer, improving research and development investments, generates novel therapies and government initiatives to increase cancer awareness. The change in the current lifestyle has led to the exposure of a large population to certain risk factors that contribute to liver cancer therapeutics market in the forecast period.

Increasing research and development activities will drive the market growth

Increasing research and development activities in developing new therapeutics for liver cancer will drive the market growth. For instance, National Clinical Trial (NCT) Registry 2020, the Hoffmann-La Roche Ltd., has started the phase Ib/II study to assess of efficacy and safety of the multiple immunotherapy-based treatment combinations with advanced liver cancer (Morpheus-Liver). The trial was started in November of 2020 and is expected to complete in July 2024.

In the United States, increasing research and development activities in developing novel therapeutics for the liver are expected to drive market growth in the forecast period. For instance, in May 2020, Food and Drug Administration (FDA) has approved atezolizumab (Tecentriq) and bevacizumab (Avastin) as initial treatments for people with liver cancer that has spread or that can't be treated with surgery.

Pharmaceutical companies are utilizing approaches to maintain the balance between supply and demand. For instance, the American Society of Clinical Oncology, the European Society of Medical Oncology and the National Institute of Health and Care Excellence has proposed the guidelines. These factors are driving the market growth in the forecast period.

The rising burden of liver cancer across the globe is driving the market growth

The increasing incidence of liver cancer is expected to expedite the growth of the market during the forecast period. Alcohol & tobacco consumption, smoking, and environmental factors in developed nations are some of the reasons for the prevalence of cancer. The increasing urbanization is expected to bolster the healthy growth of the market in the forecast period.

According to the GLOBOCAN data, globally, in 2020, there were around 905,677 (4.7%) new liver cancer cases and 830,180 (8.3%) deaths due to liver cancer. Moreover, the high demand for therapeutic drugs for liver cancer will create wide opportunities for the market players to produce more drugs, and thereby, the market is expected to witness a significant growth over the forecast period.

Side effects associated with certain medications coupled with high cost of cancer treatment

However, there are many side effects are inconvenient or upsetting but are not harmful to health. But some side effects has severe medical conditions. Side effects can vary from person to person and from treatment to treatment, to the extent that two people receiving the same treatment may experience very different side effects. Some experience side effects that arise during treatment and improve over time, which is the most common scenario. But some people experience severe side effects that last for months or even years after treatment is completed.

Side-effects such as radiation therapy can bring hair loss (sometimes called alopecia) to the part of the body receiving radiation. At the same time, chemotherapy can lead to hair loss in the head, scalp, and other body parts. Various chemotherapy medications can cause several types of hair loss or no hair loss at all. Hair loss usually happens within two weeks of treatment, worsening over the first month or two of ongoing treatment.

COVID-19 Impact Analysis

According to the CDC, the senior population with underlying severe therapeutic conditions, including people with liver cancer, might be at higher risk for severe illness from COVID-19. Patients with hepatocellular carcinoma are at higher risk for severe COVID-19 than those without hepatocellular carcinoma.

According to a research article by Hidenori Toyoda et al., published in Hepatology Communications Journal 2020, during the COVID-19 pandemic 2020, strict measures were implemented by the government to prevent the spread of COVID-19, which adversely affected the routine monitoring of chronic liver disease such as hepatocellular carcinoma (HCC). Therefore, these patients were considered in the emergency category during the pandemic. Besides, the increased sales of cancer products will foster healthy growth of the market amid COVID-19.

Segment Analysis

Hepatocellular Carcinoma segment is expected to grow at the fastest CAGR during the forecast period (2021-2028)

Hepatocellular carcinoma is the typical type of liver cancer. It happens most often in people with chronic liver diseases, such as cirrhosis begun by hepatitis B or hepatitis C disease. The risk of hepatocellular carcinoma, the most basic type of liver cancer, is higher in people with long-term liver infections. It's also more eminent if the liver is scarred by disease with hepatitis B or hepatitis C. Hepatocellular carcinoma is more common in people who drink large amounts of alcohol and who have an increase of fat in the liver.

According to a research study by Giuliana Amadeo et al., printed in JHEP Reports Journal 2021, the study was carried in 6 referral centers in the metropolitan area of Paris, France, to assess the result COVID-19 pandemic on the supervision of patients with hepatocellular carcinoma (HCC). The study outcomes found that in a metropolitan area of Paris, hepatocellular carcinoma (HCC) patients were highly influenced by the COVID-19 pandemic.

Many key payers are devloping new drugs for the cure of this disease. For instance, in August 2018, Eisai Inc. received U.S. Food and Drug Administration (FDA) approval for lenvatinib (Lenvima) for patients with unresectable hepatocellular carcinoma (HCC). Hence, the rising incidence of cancer and high unmet medical needs are the major factors that drive the segment growth over the forecast period..

The chemotherapy segment are expected to dominate the liver cancer therapeutics market during the forecast period

Chemotherapy is the use of anti-cancer medications used to treatment of cancerous cells. Chemotherapy has been done for many years and is one of the most prevalent cancer treatments. In most instances, chemotherapy works by preventing the cancer cell's ability to grow or multiply. Several groups of medications work in many ways to fight cancer cells. Chemotherapy may be used alone for some types of cancer or in sequence with other treatments such as radiation or surgery. Often, a mixture of chemotherapy drugs is used to fight particular cancer. Some chemotherapy drugs are given in a specific amount depending on the type of cancer used for treatment.

While chemotherapy can be quite efficient in treating specific cancers, chemotherapy medications reach all body parts. The carcinoma cells that cause may be many side effects during therapy.

Geographical Analysis

North America region holds the largest market share global liver cancer therapeutics market

North America region is dominating the global liver cancer therapeutics market accounted for the largest market share in 2020, owing to the growing incidence of liver cancer, the presence of key market players, and the launch of new commodities influence market growth in the region.

According to the Centers for Disease Control and Prevention (CDC), the senior population with underlying severe therapeutic conditions, including people with liver disease, might be at higher risk for severe illness from COVID-19.

According to the American Society of Clinical Oncology estimates, there were around 42,220 adults diagnosed with liver cancer in the United States in 2018 (of which there are 30,610 men and 11,610 women). In addition, in 2020, there were around 42,810 new liver cancer cases in the United States 2020. With the increasing cases of liver cancer in the United States, it is expected to raise demand for liver cancer therapeutics to manage the disease.

Competitive Landscape

The liver cancer therapeutics market is moderately competitive with presence of local as well as global companies. Some of the key players which are contributing to the growth of the market include Amgen, Pfizer Inc., Bristol-Myers Squibb Company, Eisai Co., Ltd., Exelixis Inc, Merck & Co. Inc., Bayer AG, F. Hoffmann-La Roche Ltd, and Celgene Corporation among others. The major players are adopting several growth strategies such as product launches, acquisitions, and collaborations, which are contributing to the growth of the liver cancer therapeutics market globally.

Amgen Inc

Overview: Amgen Inc. is an independent biotechnology medicines company that discovers, develops, manufactures and markets medicines for grievous illnesses. The Company focuses solely on human therapeutics and concentrates on innovating novel medicines based on advances in cellular and molecular biology.

Product Portfolio: The Company's portfolio comprised of inflammation, oncology/hematology, bone health, cardiovascular disease, and nephrology and neuroscience areas.

Why Purchase the Report?

  • Visualize the composition of the liver cancer therapeutics market segmentation by type, therapy and end user highlighting the key commercial assets and players.
  • Identify commercial opportunities in liver cancer therapeutics market by analyzing trends and co-development deals.
  • Excel data sheet with thousands of data points of liver cancer therapeutics market - level 4/5 segmentation.
  • PDF report with the most relevant analysis cogently put together after exhaustive qualitative interviews and in-depth market study.
  • Product mapping in excel for the key product of all major market players

The global liver cancer therapeutics market report would provide an access to an approximately 45+ market data table, 40+ figures and 180 pages.

Target Audience

  • Service Providers/ Buyers
  • Industry Investors/Investment Bankers
  • Education & Research Institutes
  • Research Professionals
  • Emerging Companies
  • Manufacturers

Market Segmentation

Global Liver Cancer Therapeutics Market - By Type

  • Hepatocellular Carcinoma
  • Cholangio Carcinoma
  • Hepatoblastoma
  • Other

Global Liver Cancer Therapeutics Market - By Therapy

  • Targeted Therapy
  • Radiation Therapy
  • Immunotherapy
  • Chemotherapy

Global Liver Cancer Therapeutics Market - By End User

  • Hospitals
  • Clinics
  • Ambulatory Surgical Centers

Global Liver Cancer Therapeutics Market - By Region

  • North America
  • South America
  • Europe
  • Asia Pacific
  • Middle East & Africa

Table of Contents

1. Global Liver Cancer Therapeutics Market Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Global Liver Cancer Therapeutics Market - Market Definition and Overview

3. Global Liver Cancer Therapeutics Market - Executive Summary

  • 3.1. Market Snippet by Type
  • 3.2. Market snippet by Therapy
  • 3.3. Market Snippet by End User
  • 3.4. Market Snippet by Region

4. Global Liver Cancer Therapeutics Market - Market Dynamics

  • 4.1. Market Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Increasing research and development activities will drive the market growth
      • 4.1.1.2. The rising burden of liver cancer across the globe is driving the market growth
    • 4.1.2. Restraints:
      • 4.1.2.1. Side effects associated with certain medications coupled with high cost of cancer treatment
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Global Liver Cancer Therapeutics Market - Industry Analysis

  • 5.1. Porter's Five Forces Analysis
  • 5.2. Supply Chain Analysis
  • 5.3. Pricing Analysis
  • 5.4. Regulatory Analysis
  • 5.5. Reimbursement Analysis
  • 5.6. Unmet Needs

6. Global Liver Cancer Therapeutics Market - COVID-19 Analysis

  • 6.1. Analysis of Covid-19 on the Market
    • 6.1.1. Before COVID-19 Market Scenario
    • 6.1.2. Present COVID-19 Market Scenario
    • 6.1.3. After COVID-19 or Future Scenario
  • 6.2. Pricing Dynamics Amid Covid-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During Pandemic
  • 6.5. Manufacturers Strategic Initiatives
  • 6.6. Conclusion

7. Global Liver Cancer Therapeutics Market - By Type

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type Segment
    • 7.1.2. Market Attractiveness Index, By Type Segment
  • 7.2. Hepatocellular Carcinoma*
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis, US$ Million, 2018-2028 and Y-o-Y Growth Analysis (%), 2020-2028
  • 7.3. Cholangio Carcinoma
  • 7.4. Hepatoblastoma
  • 7.5. Other

8. Global Liver Cancer Therapeutics Market - By Therapy

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Therapy
    • 8.1.2. Market Attractiveness Index, By Therapy
  • 8.2. Targeted Therapy*
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis, US$ Million, 2018-2028 and Y-o-Y Growth Analysis (%), 2020-2028
  • 8.3. Radiation Therapy
  • 8.4. Immunotherapy
  • 8.5. Chemotherapy

9. Global Liver Cancer Therapeutics Market - By End User

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User Segment
    • 9.1.2. Market Attractiveness Index, By End User Segment
  • 9.2. Hospitals *
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis, US$ Million, 2018-2028 and Y-o-Y Growth Analysis (%), 2020-2028
  • 9.3. Clinics
  • 9.4. Ambulatory Surgical Centers

10. Global Liver Cancer Therapeutics Market - By Region

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis, US$ Million, 2018-2028 and Y-o-Y Growth Analysis (%), 2020-2028, By Region
    • 10.1.2. Market Attractiveness Index, By Region
  • 10.2. North America
    • 10.2.1. Introduction
    • 10.2.2. Key Region-Specific Dynamics
    • 10.2.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
    • 10.2.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Therapy
    • 10.2.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
    • 10.2.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.2.6.1. U.S.
      • 10.2.6.2. Canada
      • 10.2.6.3. Mexico
  • 10.3. Europe
    • 10.3.1. Introduction
    • 10.3.2. Key Region-Specific Dynamics
    • 10.3.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
    • 10.3.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Therapy
    • 10.3.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
    • 10.3.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.3.6.1. Germany
      • 10.3.6.2. U.K.
      • 10.3.6.3. France
      • 10.3.6.4. Italy
      • 10.3.6.5. Spain
      • 10.3.6.6. Rest of Europe
  • 10.4. South America
    • 10.4.1. Introduction
    • 10.4.2. Key Region-Specific Dynamics
    • 10.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
    • 10.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Therapy
    • 10.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
    • 10.4.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.4.6.1. Brazil
      • 10.4.6.2. Argentina
      • 10.4.6.3. Rest of South America
  • 10.5. Asia Pacific
    • 10.5.1. Introduction
    • 10.5.2. Key Region-Specific Dynamics
    • 10.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
    • 10.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Therapy
    • 10.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
    • 10.5.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.5.6.1. China
      • 10.5.6.2. India
      • 10.5.6.3. Japan
      • 10.5.6.4. Australia
      • 10.5.6.5. Rest of Asia Pacific
  • 10.6. Middle East and Africa
    • 10.6.1. Introduction
    • 10.6.2. Key Region-Specific Dynamics
    • 10.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
    • 10.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Therapy
    • 10.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User

11. Global Liver Cancer Therapeutics Market - Competitive Landscape

  • 11.1. Key Developments and Strategies
  • 11.2. Company Share Analysis
  • 11.3. Product Benchmarking
  • 11.4. List of key companies to watch
  • 11.5. List of the company with disruptive technology
  • 11.6. List of start-up companies

12. Global Liver Cancer Therapeutics Market- Company Profiles

  • 12.1. Amgen Inc. *
    • 12.1.1. Company Overview
    • 12.1.2. Product Portfolio and Description
    • 12.1.3. Key Highlights
    • 12.1.4. Financial Overview
  • 12.2. AstraZeneca PLC
  • 12.3. Bayer AG
  • 12.4. Celgene Corporation
  • 12.5. Eli Lilly
  • 12.6. Bristol-Myers Squibb Company
  • 12.7. Gilead Sciences, Inc.
  • 12.8. Takeda Pharmaceutical Company Limited
  • 12.9. Daiichi Sankyo Company, Limited
  • 12.10. UCB SA

LIST NOT EXHAUSTIVE

13. Global Liver Cancer Therapeutics Market - DataM

  • 13.1. Appendix
  • 13.2. About Us and Services
  • 13.3. Contact Us
Back to Top
전화 문의
F A Q